• A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020, in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    Coherus wins FDA approval for second Lucentis biosimilar, its third drug

    The biotech company secured a valuable interchangeable designation for the copycat medicine, which it plans to launch later this year.

    By Kristin Jensen • Aug. 3, 2022
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images

    With new data, Roche takes step toward more convenient cancer immunotherapy

    The pharma claimed Phase 3 study success for a subcutaneous version of its drug Tecentriq, a strategy it and rivals Merck and Bristol Myers could use to extend the market life of their lucrative drugs.

    By Aug. 2, 2022
  • A general view of AstraZeneca is seen during Prime Minister Scott Morrison's visit on August 19, 2020 in Sydney, Australia.
    Image attribution tooltip
    Lisa Maree Williams via Getty Images

    AbbVie cancer drug sales fall as AstraZeneca competitor gains ground

    Imbruvica, long one of AbbVie’s top-selling medicines, has ceded market share in treating chronic lymphocytic leukemia to AstraZeneca’s Calquence.

    By July 29, 2022
  • Image attribution tooltip
    Dan Kitwood via Getty Images

    Pfizer sales of COVID-19 vaccine, pill beat forecasts as company prepares for future waves

    The company plans to ready a booster shot by the fall that targets the BA.4 and BA.5 strains that are currently most prevalent in the U.S. and other countries.

    By Updated July 28, 2022
  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical

    Teva reaches deal in principle to settle opioid lawsuits for over $4B

    The generics maker joins other pharmaceutical companies attempting to resolve litigation over their alleged contributions to the opioid epidemic.

    By Kristin Jensen • July 27, 2022
  • Amazon will see you now: reading between the lines of the One Medical acquisition

    The deal’s near-term effects might not be large, but Amazon’s acquisition still threaten’s One Medical’s primary care competitors and others seeking a greater slice of the market, experts said.

    By Rebecca Pifer • July 25, 2022
  • The World Health Organization emblem of a snake symbol for medicine coiling around UN symbol.
    Image attribution tooltip
    Sean Gallup via Getty Images

    EU speeds approval of monkeypox vaccine as WHO declares public health emergency

    Vaccine maker Bavarian Nordic said it is meeting demand for its shot with production capacity of 30 million doses a year.

    By July 25, 2022
  • Amazon's corporate logo
    Image attribution tooltip

    Amazon to buy One Medical for $3.9B

    The all-cash deal for the San Francisco-based company follows months of speculation about a potential acquisition, but Amazon as the buyer comes as a surprise.

    By Rebecca Pifer • July 21, 2022
  • A CDC sign on the agency's exterior building
    Image attribution tooltip
    Jessica McGowan/Getty Images via Getty Images

    CDC backs Novavax's protein-based vaccine for COVID-19

    Health officials argue a new type of shot could help to persuade unvaccinated people, although some surveys suggest that might not be the case. 

    By July 20, 2022
  • Group of people working in a modern board room with augmented reality interface, all objects in the scene are 3D.
    Image attribution tooltip
    piranka via Getty Images

    Ultragenyx sells rare disease drug royalties to Canadian pension fund

    In exchange for $500 million, the fund, called OMERS, will get a 30% royalty on future sales of Ultragenyx’s drug Crysvita in the U.S. and Canada, where it’s approved to treat two rare conditions.

    By July 15, 2022
  • A 3D illustration of human lungs.
    Image attribution tooltip
    yodiyim via Getty Images

    Royalty Pharma buys rights to top-selling GSK drug in pair of deals

    The prolific biopharma dealmaker is paying Theravance $1.1 billion and Innoviva $282 million to acquire rights to royalties on GSK’s asthma and COPD drug Trelegy Ellipta.

    By Kristin Jensen • July 14, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    BioMarin's hemophilia gene therapy recommended for approval in Europe

    The decision brings what could be the first approved hemophilia gene therapy, Roctavian, closer to market, after a series of regulatory setbacks that have delayed its arrival. 

    By June 24, 2022
  • A 3D rendered image of a neuron cell network on black background.
    Image attribution tooltip
    koto_feja via Getty Images

    Amylyx's ALS drug gets approved in Canada

    The Massachusetts-based biotech is awaiting a decision in the U.S., where the FDA recently extended its review after agency advisers narrowly voted against the treatment.

    By June 13, 2022
  • Line graph with collage image of headshots in the background
    Image attribution tooltip
    Permission granted by Fizkes, OM1
    Sponsored by OM1

    Real-world data: A health equity lens for research

    Arising from the circumstances in which people grow, live, work and age, and the systems put in place to deal with illness, these health inequities are avoidable. 

    By Jessica Paulus, ScD, Senior Director, Epidemiology, OM1 • June 13, 2022
  • FTC
    Image attribution tooltip
    Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.

    FTC to investigate CVS Caremark, others in probe of PBM business practices

    The decision to launch an inquiry reversed a vote earlier this year, when FTC commissioners had deadlocked over whether to look into the drug pricing middlemen.

    By Rebecca Pifer • June 7, 2022
  • Image attribution tooltip

    Amarin turns to job cuts as generics challenge its heart pill

    Facing greater competition and declining sales in the U.S., the drugmaker is laying off about 40% of its workforce as part of an effort to save $100 million over the next year.

    By June 6, 2022
  • Regeneron buys control of cancer drug Libtayo from Sanofi

    The biotech, which has been partnered with Sanofi for years, will pay $900 million upfront to gain sole control of the cancer immunotherapy.

    By Updated June 2, 2022
  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Moderna vaccine sales surpass expectations as company looks to fall boosters

    The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.

    By May 4, 2022
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers wins FDA approval for first drug to treat inherited heart condition

    Bristol Myers paid $13 billion to acquire the drug's maker, MyoKardia, and expects it to become a blockbuster. But a tricky dosing regimen, as well as safety concerns, could challenge the pharmaceutical giant's lofty forecast. 

    By April 28, 2022
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen

    Biogen pulls European application for Aduhelm in another setback for the Alzheimer's drug

    In a letter to regulators, Biogen said it chose to withdraw its approval filing after discussions with the EMA, which previously found the data supporting Aduhelm to be lacking.

    By , April 22, 2022
  • department of justice building
    Image attribution tooltip
    bpperry via Getty Images

    DOJ cracks down on 'largest and most wide-ranging' COVID-19 fraud

    Defendants, including doctors, medical business executives and fake vaccination card manufacturers, caused nearly $150 million in false billings to federal programs, the DOJ said. 

    By Rebecca Pifer • April 21, 2022
  • Image attribution tooltip
    Permission granted by GoodRx
    Sponsored by GoodRx

    Inflation is forcing prioritization of healthcare spending — are you ready?

    Inflation means your customers' money doesn't travel as far as it did a few weeks ago.

    April 18, 2022
  • A child plays EndeavorRx on a tablet. The digital therapeutic intended to improve attention in kids with ADHD.
    Image attribution tooltip
    Permission granted by Akili Interactive
    Deep Dive

    Can digital therapeutics be profitable?

    Licensing deals with pharmaceutical companies were an early strategy for digital health companies, but not all of them have lasted.

    By Elise Reuter • April 11, 2022
  • Image attribution tooltip

    Sponsored by Acceleration Point

    The power of alerts

    As medical affairs continues to invest in systems and data, it can quickly become overwhelming to keep up with it all.

    April 11, 2022
  • Image attribution tooltip
    Getty Images

    Medicare finalizes policy limiting coverage of Biogen Alzheimer's drug

    Biogen said it is considering its options following CMS' decision, which restricts reimbursement of Aduhelm to patients enrolled in a randomized clinical trial. 

    By Updated April 7, 2022